洛伐他汀在基于人群的肌萎缩侧索硬化研究和小鼠模型中的保护作用
该研究采用药物流行病学与ALS小鼠模型相结合的方法,在2009年美国 Medicare 66至90岁受益人中构建病例对照研究,纳入1,128例新发运动神经元病病例和56,400名匹配对照,发现洛伐他汀与MND呈反向剂量反应关系,40 mg/日时风险降低28%;在SOD1G93A小鼠中,洛伐他汀延迟发病并延长生存,而柳氮磺吡啶和替米沙坦无获益。
要点
- 洛伐他汀与MND风险呈反向剂量反应关系,40 mg/日时风险降低28%。
- SOD1G93A小鼠中洛伐他汀延迟发病、延长生存并减少腹角运动神经元丢失。
- 柳氮磺吡啶和替米沙坦在SOD1G93A小鼠中未显示获益。
核心结论
- 洛伐他汀降低人类ALS风险,并在ALS小鼠模型中通过延迟症状发作、延长生存和保留运动神经元得到证实。
- 尽管需要进一步研究以理解机制,洛伐他汀可能代表ALS患者的潜在神经保护疗法。
- 这些数据证明药物流行病学与小鼠模型相结合方法的实用性。
研究设计与样本
- 构建大型、基于人群的病例对照研究,调查2009年美国 Medicare 66至90岁受益人中的运动神经元病(MND)。
- 纳入1,128例新发MND病例和56,400名按年龄、性别、种族和民族匹配的对照。
- 计算2006至2007年(诊断/参照前>1年)Part D(药房)索赔中>1,000种活性成分的MND相对风险。
- 采用综合筛选方法选择药物在SOD1G93A小鼠中测试:柳氮磺吡啶、替米沙坦和洛伐他汀。
- 在无力发作前通过皮下渗透泵给予小鼠人体剂量等效的药物或溶媒,评估体重、步态和生存,并在额外小鼠中进行组织学研究。
主要发现
- 观察到既往已建立的MND医学关联,以及洛伐他汀与MND之间的反向剂量反应关联,40 mg/日时风险降低28%。
- 在SOD1G93A小鼠研究中,柳氮磺吡啶和替米沙坦未带来获益,而洛伐他汀治疗延迟发病并延长生存。
- 洛伐他汀治疗的小鼠还显示小胶质细胞增生、错误折叠SOD1和腹角脊髓运动神经元丢失减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to use a novel combined pharmacoepidemiologic and amyotrophic lateral sclerosis (ALS) mouse model approach to identify potential motor neuron protective medications. METHODS: We constructed a large, population-based case-control study to investigate motor neuron disease (MND) among US Medicare beneficiaries aged 66 to 90 in 2009. We included 1,128 incident MND cases and 56,400 age, sex, race, and ethnicity matched controls. We calculated MND relative risk for >1,000 active ingredients represented in Part D (pharmacy) claims in 2006 to 2007 (>1 year before diagnosis/reference). We then applied a comprehensive screening approach to select medications for testing in SOD1G93A mice: sulfasalazine, telmisartan, and lovastatin. We treated mice with the human dose equivalent of the medication or vehicle via subcutaneous osmotic pump before onset of weakness. We then assessed weight, gait, and survival. In additional mice, we conducted histological studies. RESULTS: We observed previously established medical associations for MND and an inverse dose-response association between lovastatin and MND, with 28% reduced risk at 40 mg/day. In SOD1G93A mouse studies, sulfasalazine and telmisartan conferred no benefit, whereas lovastatin treatment delayed onset and prolonged survival. Lovastatin treated mice also had less microgliosis, misfolded SOD1, and spinal motor neuron loss in the ventral horn. INTERPRETATION: Lovastatin reduced the risk of ALS in humans, which was confirmed in an ALS mouse model by delayed symptom onset, prolonged survival, and preservation of motor neurons. Although further studies to understand the mechanism are required, lovastatin may represent a potential neuroprotective therapy for patients with ALS. These data demonstrate the utility of a combined pharmacoepidemiologic and mouse model approach. ANN NEUROL 2023;93:881-892.
引用
- Kreple CJ, Searles Nielsen S, Schoch KM, et al. Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model. Ann Neurol. 2023. PMID: 36627836. doi:10.1002/ana.26600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。